共 64 条
[1]
Wedge SR(2002)ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 4645-4655
[2]
Ogilvie DJ(2002)ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Res 62 7284-7290
[3]
Dukes M(2003)Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin Cancer Res 9 1546-1556
[4]
Carlomagno F(1997)The biology of vascular endothelial growth factor Endocr Rev 18 4-25
[5]
Vitagliano D(2006)Vascular endothelial growth factor signaling pathways: therapeutic perspective Clin Cancer Res 12 5018-5022
[6]
Guida T(1999)EGF receptor Int J Biochem Cell Biol 31 637-643
[7]
Ciardiello F(2012)Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary Clin Cancer Res 18 3722-3730
[8]
Caputo R(2012)Pharmacokinetics of vandetanib: three phase I studies in healthy subjects Clin Ther 34 221-237
[9]
Damiano V(2011)Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole Drugs R D 11 37-51
[10]
Ferrara N(2010)Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment Clin Pharmacokinet 49 607-618